Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Apr 22, 2021 1:44pm
58 Views
Post# 33045980

RE:Christian talking at 4th Global Liver Congress

RE:Christian talking at 4th Global Liver Congress

The regulators are talking at this meeting too. Maybe something new???

It looks like a more holistic conference (science, industry, regulatory) than some of the others.


qwerty22 wrote:

https://www.global-engage.com/event/nash/

You can access the agenda by clicking on 'read the agenda'. (I registered with totally made-up details)

Here is the blurb on Christian's presentation.


 

CHRISTIAN MARSOLAIS
Senior Vice President and Chief Medical Officer, Theratechnologies, Canada
Treating NASH through a unique mode of action with tesamorelin
Tesamorelin is a Growth Hormone Releasing Hormone (GHRH) Analog indicated
for the treatment of visceral adipose tissue accumulation in People Living with HIV. Tesamorelin,with over 10 years of real-life data,has a well-established safety and efficacy profile.It has a significant impact on the accumulation of ectopic fat, reduction of visceral adipose tissue, reduction of fat accumulation inthe muscle (trunkmusclegroup) and decrease of liver fat accumulation while increasing lean body mass. Based on transcriptomic analysis of liver biopsies, tesamorelin was shown to have significant impact on oxidative phosphorylation, inflammatory makers related to fibrosis, and improvements in gene expression related to favorable hepatocellular carcinoma prognosis. Tesamorelin is currently being evaluated as an investigational treatment for all people living with nonalcoholic steatohepatitis (NASH).


<< Previous
Bullboard Posts
Next >>